Conviva Announces Streaming Platform Expansion Solving Audience Measurement Challenges Globally
20.10.2021 21:00:00 EEST | Business Wire | Press release
Conviva, the continuous measurement platform for streaming media, today announces the availability of its technology and real-time data to enable end-to-end advertising audience measurement for its publisher customers and their ecosystem partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005928/en/
Conviva's streaming platform expansion delivers purpose-built technology and real-time data to enable end-to-end advertising audience measurement for publisher customers and their ecosystem partners. (Grapic: Business Wire)
Conviva’s global streaming audience measurement technology promises to deliver unique, innovative, and industry-changing solutions based on:
Session-level and census-level measurement
Antiquated third-party web technologies like beacons, logs, pixels or outdated and inaccurate panel methodologies are incapable of dealing with today’s complex device fragmentation. Conviva’s Stream Sensor™ provides continuous collection of every single session using standardized data collection and processing techniques for both session-level and census-level comprehensiveness. This provides a foundation of complete, comprehensive, uniform data that the entire ecosystem can rely on for accurate audience measurement, by eliminating inaccuracies within statistical inferences.
Future-proofed identity
Identity, a necessary pillar for accurate advertising audience measurement, is increasingly unstable due to privacy-regulations, third-party interference, and the rapid growth of anonymized ad-supported viewership. Conviva’s Stream ID™ provides consistent, persistent, accurate identity solutions using the best available first-party data possible, while still accommodating consumer choice and privacy regulations globally.
Ecosystem interoperability
In order to operate effectively in the complex world of audience measurement, content syndication, and cross-platform measurement, publishers must be able to activate their streaming data and audience with multiple ecosystem partners. Conviva’s platform expansion supplying Stream ID, and the Stream Sensor data it carries, are built using a common identity model that creates ecosystem interoperability, from both content partners and ecosystem activation destinations.
Publisher control
For the first time in the history of digital media, premium publishers are now in full control of their streaming data and audience, no longer relying on ‘currency tax’ vendors. This will help the premium publisher ecosystem compete effectively against the hegemony of walled gardens by giving advertisers the audience and context they need to address brand safety concerns.
Conviva certification
Conviva is fully committed to participating in the complete audit and accreditation processes including the Media Ratings Council (MRC) in the U.S. and other relevant industry auditing bodies globally, to certify new census-level standards that surpass any statistical inference accuracy certifications. This vital step ensures that data collection and reporting standards are upheld, to provide brands and agencies confidence in the accuracy of Conviva's audience measurement and reporting.
Conviva’s evolution is being led by the company’s recently-appointed President and CEO, Keith Zubchevich, a streaming industry veteran with more than a decade at Conviva. In his previous role as Chief Strategy Officer, Zubchevich worked closely with customers to understand their pain points and drive Conviva’s innovation to solve them, relationships that continue to inform his strategy as CEO.
“Today Conviva is already underfoot with premium publishers, collecting 3 trillion streaming events daily with insight into 500 million unique viewers globally,” comments Zubchevich. “The fact is Conviva has already solved for the incredibly complex challenge of standardized, census-level streaming measurement and is now working with our premium publishers and their ecosystem partners to introduce a new standard of audience measurement and quality to the global industry, to enable long-overdue innovation and change.”
About Conviva
Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005928/en/
Contact information
Paula Winkel
pr@conviva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
